PMID- 35586807
OWN - NLM
STAT- MEDLINE
DCOM- 20220520
LR  - 20230204
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2022
DP  - 2022
TI  - Effective-Component Compatibility of Bufei Yishen Formula III Combined with 
      Electroacupuncture Suppresses Inflammatory Response in Rats with Chronic 
      Obstructive Pulmonary Disease via Regulating SIRT1/NF-kappaB Signaling.
PG  - 3360771
LID - 10.1155/2022/3360771 [doi]
LID - 3360771
AB  - OBJECTIVE: To explore more efficient treatments for chronic obstructive pulmonary 
      disease (COPD), effective-component compatibility of Bufei Yishen formula III 
      (ECC-BYF III) and electroacupuncture were tested on rats with COPD, and silent 
      information regulator transcript-1 (SIRT1)/nuclear factor-kappaB (NF-kappaB) 
      signaling was further investigated to interpret the therapy. METHODS: In total, 
      70 rats were randomly divided into control (Control), model (Model), 
      aminophylline (APL), ECC-BYF III, electroacupuncture (EA), ECC-BYF III+EA, and 
      sham electroacupuncture (SA) groups. Cigarette smoke exposure combined with 
      repeated bacterial infections was used to establish COPD models in 1-12 weeks. 
      From 13 to 20 weeks, the ECC-BYF III and APL groups received corresponding drugs; 
      the EA group received electroacupuncture therapy, wherein Dazhui (GV 14), Feishu 
      (BL 13), and Shenshu (BL 23) points were selected; the ECC-BYF III+EA group 
      received ECC-BYF III intragastrically combined with electroacupuncture; and the 
      SA group received simulated electroacupuncture (nonacupoint). Pulmonary function, 
      pulmonary histopathology, the expressions of SIRT1/NF-kappaB signaling, and 
      inflammation-related mRNA and protein were detected. RESULTS: Significant 
      deterioration was observed in pulmonary function and pulmonary histopathology in 
      rats with COPD (P < 0.01), and inflammatory state was illustrated by increased 
      levels of interleukin- (IL-) 6 and tumor necrosis factor alpha (TNF-alpha) and 
      decreased levels of IL-10 (P < 0.01). After the intervention of APL, ECC-BYF III, 
      EA, and ECC-BYF III+EA, both pulmonary function and pulmonary histopathology were 
      improved (P < 0.05 and P < 0.01), whereas the levels of IL-6 and TNF-alpha were 
      decreased and IL-10 was increased (P < 0.05 and P < 0.01). Additionally, the mRNA 
      expressions of IL-6, TNF-alpha, NF-kappaB, and acetylated NF-kappaBp65 (Ac-NF-kappaB) were noted 
      to decrease, and SIRT1 and IL-10 were increased (P < 0.05 and P < 0.01); the 
      protein expression of SIRT1 was upregulated, and NF-kappaBp65 and Ac-NF-kappaB were 
      downregulated (P < 0.05 and P < 0.01). The effect of ECC-BYF III+EA was better in 
      terms of improving pulmonary function and alleviating inflammation than that of 
      the other treatment groups (P < 0.01 and P < 0.05). CONCLUSIONS: ECC-BYF III, 
      electroacupuncture, and their combination can suppress inflammation, among which 
      the combination therapy has been proven to be the most effective treatment, and 
      the mechanism may be involved in activating SIRT1/NF-kappaB signaling.
CI  - Copyright (c) 2022 Fanli Jin et al.
FAU - Jin, Fanli
AU  - Jin F
AUID- ORCID: 0000-0001-6175-5667
AD  - Henan Key Laboratory of Chinese Medicine for Respiratory Disease, Henan 
      University of Chinese Medicine, Zhengzhou, Henan 450046, China.
AD  - Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases 
      Co-Constructed by Henan Province & Education Ministry of P.R. China, Zhengzhou, 
      Henan 450046, China.
AD  - Department of Respiratory Diseases, The First Affiliated Hospital of Henan 
      University of Chinese Medicine, Zhengzhou, Henan 450046, China.
FAU - Zhang, Lanxi
AU  - Zhang L
AD  - Henan Key Laboratory of Chinese Medicine for Respiratory Disease, Henan 
      University of Chinese Medicine, Zhengzhou, Henan 450046, China.
AD  - Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases 
      Co-Constructed by Henan Province & Education Ministry of P.R. China, Zhengzhou, 
      Henan 450046, China.
AD  - Department of Respiratory Diseases, The First Affiliated Hospital of Henan 
      University of Chinese Medicine, Zhengzhou, Henan 450046, China.
FAU - Chen, Kai
AU  - Chen K
AD  - Henan Key Laboratory of Chinese Medicine for Respiratory Disease, Henan 
      University of Chinese Medicine, Zhengzhou, Henan 450046, China.
AD  - Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases 
      Co-Constructed by Henan Province & Education Ministry of P.R. China, Zhengzhou, 
      Henan 450046, China.
FAU - Miao, Yufang
AU  - Miao Y
AD  - Henan Key Laboratory of Chinese Medicine for Respiratory Disease, Henan 
      University of Chinese Medicine, Zhengzhou, Henan 450046, China.
AD  - Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases 
      Co-Constructed by Henan Province & Education Ministry of P.R. China, Zhengzhou, 
      Henan 450046, China.
FAU - Liu, Yang
AU  - Liu Y
AD  - Henan Key Laboratory of Chinese Medicine for Respiratory Disease, Henan 
      University of Chinese Medicine, Zhengzhou, Henan 450046, China.
AD  - Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases 
      Co-Constructed by Henan Province & Education Ministry of P.R. China, Zhengzhou, 
      Henan 450046, China.
FAU - Tian, Yange
AU  - Tian Y
AUID- ORCID: 0000-0002-5849-4504
AD  - Henan Key Laboratory of Chinese Medicine for Respiratory Disease, Henan 
      University of Chinese Medicine, Zhengzhou, Henan 450046, China.
AD  - Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases 
      Co-Constructed by Henan Province & Education Ministry of P.R. China, Zhengzhou, 
      Henan 450046, China.
FAU - Li, Jiansheng
AU  - Li J
AUID- ORCID: 0000-0002-6485-2371
AD  - Henan Key Laboratory of Chinese Medicine for Respiratory Disease, Henan 
      University of Chinese Medicine, Zhengzhou, Henan 450046, China.
AD  - Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases 
      Co-Constructed by Henan Province & Education Ministry of P.R. China, Zhengzhou, 
      Henan 450046, China.
AD  - Department of Respiratory Diseases, The First Affiliated Hospital of Henan 
      University of Chinese Medicine, Zhengzhou, Henan 450046, China.
LA  - eng
PT  - Journal Article
DEP - 20220509
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Bu-Fei-Yi-Shen)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Interleukin-6)
RN  - 0 (NF-kappa B)
RN  - 0 (RNA, Messenger)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 130068-27-8 (Interleukin-10)
RN  - EC 3.5.1.- (Sirt1 protein, rat)
RN  - EC 3.5.1.- (Sirtuin 1)
SB  - IM
MH  - Animals
MH  - Drugs, Chinese Herbal
MH  - *Electroacupuncture
MH  - Inflammation/therapy
MH  - Interleukin-10
MH  - Interleukin-6
MH  - NF-kappa B/metabolism
MH  - *Pulmonary Disease, Chronic Obstructive/genetics
MH  - RNA, Messenger
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Sirtuin 1/genetics
MH  - Tumor Necrosis Factor-alpha/metabolism
PMC - PMC9110177
COIS- The authors declare that they have no competing interests.
EDAT- 2022/05/20 06:00
MHDA- 2022/05/21 06:00
PMCR- 2022/05/09
CRDT- 2022/05/19 02:32
PHST- 2022/03/15 00:00 [received]
PHST- 2022/04/18 00:00 [accepted]
PHST- 2022/05/19 02:32 [entrez]
PHST- 2022/05/20 06:00 [pubmed]
PHST- 2022/05/21 06:00 [medline]
PHST- 2022/05/09 00:00 [pmc-release]
AID - 10.1155/2022/3360771 [doi]
PST - epublish
SO  - Biomed Res Int. 2022 May 9;2022:3360771. doi: 10.1155/2022/3360771. eCollection 
      2022.